Oncology |
Bendamustine RTU |
|
|
180 mg/ 4 ml, 100 mg/ 4 ml |
Filed |
|
Oncology |
Bortezomib |
|
|
3.5 mg |
Filed |
|
Oncology |
Cabazitaxel |
|
|
40 mg/ml (1.5 ml) |
Filed |
|
Oncology |
Carfilzomib |
|
|
60 mg |
Filed |
|
Oncology |
Decitabine |
|
|
50 mg |
Filed |
|
Oncology |
Eribulin |
|
|
0.5 mg/ml (2 ml) |
Filed |
|
Oncology |
Fulvestrant |
|
|
50 mg/ml (5 ml) |
Filed |
|
Oncology |
Fosaprepitant |
|
|
150 mg/ ml |
Filed |
|
Oncology |
Liposomal Doxorubicin |
|
|
20 mg/10 ml ,50 mg/25 ml |
Filed |
|
Oncology |
Palonosetron |
|
|
0.075 mg/5 ml, 0.25 mg/ 5 ml |
Filed |
|
Oncology |
Pemetrexed |
|
|
100, 500, 1 gm |
Filed |
|
Oncology |
Plerixafor |
|
|
20 mg/ml (1.2 ml) |
Filed |
|
Oncology |
Zoledronic Acid |
|
|
4 mg/5 ml, 5 mg/100 ml, 4 mg/100 ml |
Filed |
|
Oncology |
Abiraterone |
|
|
250 mg |
Filed |
|
Oncology |
Capecitabine |
|
|
150 mg, 500 mg |
Filed |
|
Oncology |
Dasatinib |
|
|
20, 50, 70, 80,100 and 140 mg |
Filed |
|
Oncology |
Enzalutamide |
|
|
40 mg, 80 mg |
Under Development |
|
Oncology |
Everolimus |
|
|
2.5, 5, 7.5, 10 mg |
Filed |
|
Oncology |
Lenalidomide |
|
|
2.5, 5, 10, 15, 20, 25 mg |
Filed |
|
Oncology |
Lenvatinib |
|
|
4, 10 mg |
Under Development |
|
Oncology |
Nilotinib |
|
|
50, 150, 200 mg |
Under Development |
|
Oncology |
Palbociclib |
|
|
75, 100, 125 mg |
Filed |
|
Oncology |
Pomalidomide |
|
|
1,2,3,4 mg |
Filed |
|
Central Nervous System |
Glatiramer |
|
|
20, 40 mg |
Filed |
|
Central Nervous System |
Sugammadex |
|
|
100 mg/ml (2 ml and 5 ml) |
Filed |
|
Central Nervous System |
Pregabalin |
|
|
25, 50, 75, 100, 150, 200, 225, 300 mg |
Filed |
|
Cardiovascular |
Fondaparinux |
|
|
2.5 mg/0.5 ml, 5 mg/0.4 ml, 7.5 mg/0.6 ml and 10 mg/0.8 ml |
Filed |
|
Cardiovascular |
Treprostinil |
|
|
1 mg/ml, 2.5 mg/ml, 5 mg/ml and 10 mg/ml (20 ml) |
Filed |
|
Cardiovascular |
Apixaban |
|
|
2.5, 5mg |
Filed |
|
Cardiovascular |
Dabigatran |
|
|
75, 110, 150 mg |
Filed |
|
Cardiovascular |
Rivaroxaban |
|
|
10, 15, 20 mg |
Filed |
|
Cardiovascular |
Sacubitril/ Valsartan |
|
|
24/26, 49/51, 97/103 mg |
Filed |
|
Cardiovascular |
Ticagrelor |
|
|
60, 90 mg |
Filed |
|
Anti-Diabetic |
Liraglutide |
|
|
6mg/ml – 3 ml fill pen |
Under Development |
|
Anti-Diabetic |
Canagliflozin + Metformin |
|
|
150 mg/1000 mg, 150 mg/500 mg, 50mg/1000 mg, 50 mg/500 mg |
Filed |
|
Anti-Diabetic |
Linagliptin |
|
|
5 mg |
Filed |
|
Anti-Diabetic |
Linagliptin + Metformin |
|
|
2.5 mg/500 mg, 2.5 mg/850 mg, 2.5 mg/1000 mg |
Filed |
|
Gastro-Intestinal |
Esomeprazole |
|
|
20, 40mg |
Filed |
|
Gastro-Intestinal |
Esomeprazole MG + Naproxen Na |
|
|
20 mg/375 mg, 20 mg/500 mg |
Filed |
|
Others |
Daptomycin |
|
|
350, 500 mg |
Filed |
|
Others |
Icatibant |
|
|
30 mg base /3 ml PFS |
Filed |
|
Others |
Iron Sucrose |
|
|
100 mg/5 ml, 200 mg/10 ml, 50 mg/2.5 ml |
Filed |
|
Others |
Sevelamer Carbonate |
|
|
800 mg |
Filed |
|
Central Nervous System |
Fingolimod |
|
|
0.5 mg |
Filed |
|
Oncology |
Abiraterone |
|
|
250 mg, 500 mg |
Filed |
|
Oncology |
Imatinib Mesylate |
|
|
100 MG AND 400 MG |
Filed |
|
Oncology |
Carmustine |
|
|
100 mg/vial |
Filed |
|
Oncology |
Venetoclax |
|
|
10 mg, 50 mg and 100 mg |
Filed |
|
Oncology |
Sorafenib |
|
|
200 mg |
Filed |
|
Oncology |
Midostaurin |
|
|
25 mg |
Filed |
|
Oncology |
Sunitinib Malate |
|
|
12.5 mg, 25 mg, 37.5 mg and 50 mg |
Filed |
|
Oncology |
Nano Paclitaxel |
|
|
100mg |
Under Development |
|
Oncology |
Axitinib |
|
|
1mg, 3mg, 5mg, 7mg |
Under Development |
|
Oncology |
Cabozantinib |
|
|
20 mg, 40 mg and 60 mg |
Under Development |
|
Oncology |
Sunitinib |
|
|
12.5Mg;25Mg;37.5Mg;50Mg |
Filed |
|
Oncology |
Tofacitinib XR |
|
|
22 mg |
Under Development |
|
Oncology |
Pazopanib |
|
|
200 and 400 mg |
Under Development |
|
Central Nervous System |
Dimethyl Fumarate |
|
|
120mg, 240mg |
Under Development |
|
Oncology |
Nintedanib |
|
|
100 mg & 150 mg |
Under Development |
|
Oncology / Acromegaly |
Octerotide |
|
|
10mg, 20mg & 30mg |
Under Development |
|
Oncology / Acromegaly |
Lanreotide |
|
|
60mg/0.2mL, 90mg/0.3mL and 120mg/0.5mL |
Under Development |
|
Cardiovascular |
Icosapent Ethy |
|
|
1 g |
Filed |
|
Anti-Diabetic |
Semaglutide |
|
|
1.34 mg/ml (1.5 ml and 3 ml) |
Filed |
|
Anti-Obesity |
Liraglutide |
|
|
6mg/ml – 3 ml fill pen |
Under Development |
|
Gastro-Intestinal |
Lansoprazole ODT |
|
|
15 mg and 30 mg |
Filed |
|
Immuno Suppressant |
Sirolimus |
|
|
1 mg and 2 mg |
Filed |
|
Immuno Suppressant |
Tacrolimus |
|
|
0.5 mg, 1 mg and 5 mg |
Filed |
|
Others |
Valganciclovir |
|
|
450 mg |
Filed |
|
Others |
Isotretinoin |
|
|
10mg, 20mg, 30mg and 40mg |
Filed |
|
Others |
Varenicline |
|
|
0.5 mg and 1 mg |
Filed |
|
Others |
Ferric Carboxy Maltose |
|
|
50mg/mL |
Under Development |
|
Others |
Teriparatide |
|
|
0.25 mg/ml (2.4 ml) |
Filed |
|
Others |
Rifaximine |
|
|
550mg |
Under Development |
|
Others |
Amphotericin B |
|
|
50mg |
Under Development |
|
Others |
Mesalamine |
|
|
250 and 500 mg |
Under Development |
|
Oncology |
Azacitidine |
|
|
100 mg |
Filed |
|
Oncology |
Bendamustine |
|
|
25, 100mg |
Filed |
|
Others |
阿普斯特 |
|
|
10, 20, 30 mg |
Filed |
|
Oncology |
Liposomal Doxorubicin |
|
|
2 mg/ml (10 ml and 25 ml) |
Filed |
|
Oncology |
Doxorubicin Hydrochloride Liposome Injection, 20 mg/10 ml (2 mg/ml) and 50 mg/25 ml (2 mg/ml) Single-dose Vials |
|
|
20 mg/10 ml (2 mg/ml) and 50 mg/25 ml (2 mg/ml) Single-dose Vials |
Available |
|
Oncology |
Capecitabine Tablets 150 mg |
|
|
150 mg, 500 mg |
Filed |
|
Oncology |
Sunitinib Malate |
|
|
12.5, 25, 37.5 and 50 mg |
Filed |
|
Immuno Suppressant |
Sirolimus |
|
|
1 mg and 2 mg |
Filed |
|
Oncology |
Bortezomib |
|
|
3.5 mg |
Filed |
|
Oncology |
Busulfan |
|
|
6 mg/ml (10 ml) |
Filed |
|
Oncology |
Olaparib |
|
|
100 mg and 150 mg |
Under Development |
|
Oncology |
Pazopanib |
|
|
200 and 400 mg |
Under Development |
|
Central Nervous System |
Edaravone |
|
|
60 mg/100 ml |
Filed |
|
Central Nervous System |
Topiramate ER |
|
|
25, 50, 100 and 200 mg |
Filed |
|
Cardiovascular |
Tafamidis Meglumine |
|
|
20 mg |
Under Development |
|
Cardiovascular |
Edoxaban |
|
|
15 mg, 30 mg, 60 mg |
Under Development |
|
Cardiovascular |
Bempedoic acid |
|
|
120 mg, 240 mg |
Under Development |
|
Cardiovascular |
Bempedoic acid Ezetimibe |
|
|
180 mg/10 mg |
Under Development |
|
Anti-Diabetic |
Sitagliptin HCL |
|
|
25, 50, 100 mg |
Filed |
|
Anti-Diabetic |
Sitagliptin Phosphate |
|
|
25, 50, 100 mg |
Filed |
|
Anti-Diabetic |
Sitagliptin HCL + Metformin |
|
|
50 + 500, 50 + 850 |
Under Development |
|
Anti-Diabetic |
Sitagliptin Phosphate + Metformin |
|
|
50 + 500, 50 + 1000 mg |
Filed |
|
Others |
Apremilast |
|
|
10, 20, 30 mg |
Filed |
|
Others |
Posaconazole |
|
|
100 mg |
Filed |
|
Others |
Naproxen Sodium |
|
|
275 mg, 550 mg |
Filed |
|
Others |
Amphotericin B |
|
|
50 mg |
Under Development |
|
Others |
Mesalamine |
|
|
250 and 500 mg |
Under Development |
|
Oncology |
Bortezomib |
|
|
3.5 mg |
Filed |
|
Oncology |
Bortezomib |
|
|
3.5 mg |
Filed |
|
Oncology |
Bortezomib |
|
|
3.5 mg |
Filed |
|
Oncology |
Bortezomib |
|
|
3.5 mg |
Filed |
|
Oncology |
Busulfan |
|
|
6 mg/ml (10 ml) |
Filed |
|
Oncology |
Busulfan |
|
|
6 mg/ml (10 ml) |
Filed |
|
Oncology |
Busulfan |
|
|
6 mg/ml (10 ml) |
Filed |
|
Oncology |
Busulfan |
|
|
6 mg/ml (10 ml) |
Filed |
|
Oncology |
Olaparib |
|
|
100 mg and 150 mg |
Under Development |
|
Oncology |
Olaparib |
|
|
100 mg and 150 mg |
Under Development |
|
Oncology |
Olaparib |
|
|
100 mg and 150 mg |
Under Development |
|
Oncology |
Olaparib |
|
|
100 mg and 150 mg |
Under Development |
|
Oncology |
Pazopanib |
|
|
200 and 400 mg |
Under Development |
|
Oncology |
Pazopanib |
|
|
200 and 400 mg |
Under Development |
|
Oncology |
Pazopanib |
|
|
200 and 400 mg |
Under Development |
|
Oncology |
Pazopanib |
|
|
200 and 400 mg |
Under Development |
|
Central Nervous System |
Edaravone |
|
|
60 mg/100 ml |
Filed |
|
Central Nervous System |
Edaravone |
|
|
60 mg/100 ml |
Filed |
|
Central Nervous System |
Edaravone |
|
|
60 mg/100 ml |
Filed |
|
Central Nervous System |
Edaravone |
|
|
60 mg/100 ml |
Filed |
|
Central Nervous System |
Topiramate ER |
|
|
25, 50, 100 and 200 mg |
Filed |
|
Central Nervous System |
Topiramate ER |
|
|
25, 50, 100 and 200 mg |
Filed |
|
Central Nervous System |
Topiramate ER |
|
|
25, 50, 100 and 200 mg |
Filed |
|
Central Nervous System |
Topiramate ER |
|
|
25, 50, 100 and 200 mg |
Filed |
|
Cardiovascular |
Tafamidis Meglumine |
|
|
20 mg |
Under Development |
|
Cardiovascular |
Tafamidis Meglumine |
|
|
20 mg |
Under Development |
|
Cardiovascular |
Tafamidis Meglumine |
|
|
20 mg |
Under Development |
|
Cardiovascular |
Tafamidis Meglumine |
|
|
20 mg |
Under Development |
|
Cardiovascular |
Edoxaban |
|
|
15 mg, 30 mg, 60 mg |
Under Development |
|
Cardiovascular |
Edoxaban |
|
|
15 mg, 30 mg, 60 mg |
Under Development |
|
Cardiovascular |
Edoxaban |
|
|
15 mg, 30 mg, 60 mg |
Under Development |
|
Cardiovascular |
Edoxaban |
|
|
15 mg, 30 mg, 60 mg |
Under Development |
|
Cardiovascular |
Bempedoic acid |
|
|
120 mg, 240 mg |
Under Development |
|
Cardiovascular |
Bempedoic acid |
|
|
120 mg, 240 mg |
Under Development |
|
Cardiovascular |
Bempedoic acid |
|
|
120 mg, 240 mg |
Under Development |
|
Cardiovascular |
Bempedoic acid |
|
|
120 mg, 240 mg |
Under Development |
|
Cardiovascular |
Bempedoic acid Ezetimibe |
|
|
180 mg/10 mg |
Under Development |
|
Cardiovascular |
Bempedoic acid Ezetimibe |
|
|
180 mg/10 mg |
Under Development |
|
Cardiovascular |
Bempedoic acid Ezetimibe |
|
|
180 mg/10 mg |
Under Development |
|
Cardiovascular |
Bempedoic acid Ezetimibe |
|
|
180 mg/10 mg |
Under Development |
|
Anti-Diabetic |
Sitagliptin HCL |
|
|
25, 50, 100 mg |
Filed |
|
Anti-Diabetic |
Sitagliptin HCL |
|
|
25, 50, 100 mg |
Filed |
|
Anti-Diabetic |
Sitagliptin HCL |
|
|
25, 50, 100 mg |
Filed |
|
Anti-Diabetic |
Sitagliptin HCL |
|
|
25, 50, 100 mg |
Filed |
|
Anti-Diabetic |
Sitagliptin Phosphate |
|
|
25, 50, 100 mg |
Filed |
|
Anti-Diabetic |
Sitagliptin Phosphate |
|
|
25, 50, 100 mg |
Filed |
|
Anti-Diabetic |
Sitagliptin Phosphate |
|
|
25, 50, 100 mg |
Filed |
|
Anti-Diabetic |
Sitagliptin Phosphate |
|
|
25, 50, 100 mg |
Filed |
|
Anti-Diabetic |
Sitagliptin HCL + Metformin |
|
|
50 + 500, 50 + 850 |
Under Development |
|
Anti-Diabetic |
Sitagliptin HCL + Metformin |
|
|
50 + 500, 50 + 850 |
Under Development |
|
Anti-Diabetic |
Sitagliptin HCL + Metformin |
|
|
50 + 500, 50 + 850 |
Under Development |
|
Anti-Diabetic |
Sitagliptin HCL + Metformin |
|
|
50 + 500, 50 + 850 |
Under Development |
|
Anti-Diabetic |
Sitagliptin Phosphate + Metformin |
|
|
50 + 500, 50 + 1000 mg |
Filed |
|
Anti-Diabetic |
Sitagliptin Phosphate + Metformin |
|
|
50 + 500, 50 + 1000 mg |
Filed |
|
Anti-Diabetic |
Sitagliptin Phosphate + Metformin |
|
|
50 + 500, 50 + 1000 mg |
Filed |
|
Anti-Diabetic |
Sitagliptin Phosphate + Metformin |
|
|
50 + 500, 50 + 1000 mg |
Filed |
|
Others |
Apremilast |
|
|
10, 20, 30 mg |
Filed |
|
Others |
Apremilast |
|
|
10, 20, 30 mg |
Filed |
|
Others |
Apremilast |
|
|
10, 20, 30 mg |
Filed |
|
Others |
Apremilast |
|
|
10, 20, 30 mg |
Filed |
|
Others |
Posaconazole |
|
|
100 mg |
Filed |
|
Others |
Posaconazole |
|
|
100 mg |
Filed |
|
Others |
Posaconazole |
|
|
100 mg |
Filed |
|
Others |
Posaconazole |
|
|
100 mg |
Filed |
|
Others |
Naproxen Sodium |
|
|
275 mg, 550 mg |
Filed |
|
Others |
Naproxen Sodium |
|
|
275 mg, 550 mg |
Filed |
|
Others |
Naproxen Sodium |
|
|
275 mg, 550 mg |
Filed |
|
Others |
Naproxen Sodium |
|
|
275 mg, 550 mg |
Filed |
|
Others |
Amphotericin B |
|
|
50 mg |
Under Development |
|
Others |
Amphotericin B |
|
|
50 mg |
Under Development |
|
Others |
Amphotericin B |
|
|
50 mg |
Under Development |
|
Others |
Amphotericin B |
|
|
50 mg |
Under Development |
|
Others |
Mesalamine |
|
|
250 and 500 mg |
Under Development |
|
Others |
Mesalamine |
|
|
250 and 500 mg |
Under Development |
|
Others |
Mesalamine |
|
|
250 and 500 mg |
Under Development |
|
Others |
Mesalamine |
|
|
250 and 500 mg |
Under Development |
|
Oncology |
Bendamustine RTD |
|
|
45 mg/ml (4 ml) and 25 mg/ml (4 ml) |
Filed |
|
Central Nervous System |
Fingolimod |
|
|
0.5 mg |
Filed |
|
Central Nervous System |
Fingolimod |
|
|
0.5 mg |
Filed |
|
Central Nervous System |
Fingolimod |
|
|
0.5 mg |
Filed |
|
Central Nervous System |
Fingolimod |
|
|
0.5 mg |
Filed |
|
Central Nervous System |
Dimethyl Fumarate |
|
|
120mg, 240mg |
Under Development |
|
Central Nervous System |
Dimethyl Fumarate |
|
|
120mg, 240mg |
Under Development |
|
Central Nervous System |
Dimethyl Fumarate |
|
|
120mg, 240mg |
Under Development |
|
Central Nervous System |
Dimethyl Fumarate |
|
|
120mg, 240mg |
Under Development |
|
Others |
Ferric Carboxy Maltose |
|
|
50mg/mL |
Under Development |
|